Epstein-Barr Virus (EBV) is widespread and very contagious: according to the World Health Association, more than 90 percent of the global population are infected with this virus throughout their lives
The World Neglected Tropical Diseases Day on 30 January under the motto UNITE.ACT.ELIMINATE draws attention to neglected tropical diseases (NTDs) and the suffering they cause. More than one billion
AiCuris Anti-infective Cures AG and the German Center for Infection Research (DZIF) have announced the signing of a collaboration and license option agreement today. As part of the collaboration, DZIF
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug
Study shows efficacy and safety of oral antibiotic therapy in the form of pills for Staphylococcus aureus bloodstream infections. Currently, infusions are the standard treatment / published in ‘The
INCATE (the INCubator for Antibacterial Therapies in Europe) and Kineticos AMR Accelerator Fund I (KAMRA I), have announced the beginning of a new collaboration that aims to enhance the support for
Tuberculosis is currently the infectious disease that causes the most deaths worldwide. Of particular concern is the increasing emergence of multidrug-resistant tuberculosis bacteria, particularly in
Bacteria that are resistant to broad-spectrum antibiotics from the carbapenem group are increasingly posing major problems for healthcare systems worldwide. They can cause serious infections and
Darobactin is a promising candidate for the development of new, resistance-breaking antibiotics, as it has an exceptional mechanism of action and a broad spectrum of activity. In a recent study, DZIF
INCATE, the INCubator for Antibacterial Therapies in Europe, and BIOASTER, the French Technology Research Institute, have announced this week the beginning of a new partnership that aims to improve
